ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company that is developing therapies for cancer patients. The company was founded in 2014 by Charles Sawyers, Scott Lowe, and Nathanael Gray. ORIC's lead product candidate, ORIC-101, is a small molecule inhibitor of the glucocorticoid receptor that is being developed for the treatment of prostate, breast, and other cancers. The company is also developing other product candidates that target resistance mechanisms in cancer. ORIC has partnerships with AstraZeneca and others. The company has raised over $300 million in funding to date.